Shanghai RAAS Blood Products' SR604 injection enters phase IIb trial

Shanghai RAAS Blood Products Co., Ltd. [SZSE:002252] announced that its SR604 injection has entered Phase IIb clinical trials. The drug, a humanized high-affinity antibody, is designed to treat hemophilia A/B and congenital factor VII deficiency by inhibiting activated protein C. The Phase IIb trial is an open-label, multi-center study evaluating the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic profile of SR604. The trial includes both dose escalation and efficacy exploration phases. The company received approval for the clinical trial from the National Medical Products Administration (NMPA) in March 2024. SR604 is administered subcutaneously, potentially improving the treatment experience for patients compared to current intravenous factor replacement therapies. No other drugs targeting the same mechanism are currently available.